
Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>



































• Binding assay by FACS and cell based ELISA.

FACS assay shows that Anti-CCR5 antibody can bind to HEK293/Human CCR5 Stable Cell Line. HEK293/Human CCR5 Stable Cell Line was red line, Negative control HEK293 cells was grey line (QC tested).
Please contact us if you are interested in related cell pool service.
BY USE OF THIS PRODUCT, RESEARCHER AGREES TO BE BOUND BY THE FOLLOWING TERMS OF LIMITED USE OF THIS CELL LINE PRODUCT.
Emerging VoCs, Omicron, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
CD3 proteins and a collection of for bispecific antibody development which are of high specificity and bioactivities and suitable for immunization, antibody screening.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
The MABSOL biotinylated protein collection includes more than a hundred commonly studied drug targets and biomarker proteins.
Comprehensive cytokines including IL families, growth factors, chemokines, TNFs, etc. These products are HEK293 expressed and nearly in authentic structure, high purity and bioactivity, cell based assay/SPR/BLI verified.
To support preclinical/clinical immunogenicity and PK analysis, ACROBiosystems has developed a series of high-affinity anti-idiotypic antibodies. Our pipeline covers five hot targets including adalimum*b, rituxim*b, cetuxim*b, trastuzum*b, and bevacizum*b.
| English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Maraviroc | MVC; UK-427857 | Approved | Viiv Healthcare | Celsentri, Selzentry | Mainland China | HIV Infections | Godecke Gmbh | 2007-08-06 | HIV Infections; Hypertriglyceridemia; Acquired Immunodeficiency Syndrome; Hematopoietic stem cell transplantation (HSCT); Hematologic Neoplasms; Kidney Diseases; Arthritis, Rheumatoid; Graft vs Host Disease; Coronavirus Disease 2019 (COVID-19); Stroke; AIDS Dementia Complex; Cardiovascular Diseases; Inflammation; Sarcoma, Kaposi | Details |
| English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| BMS-687681 | BMS-687681 | Phase 1 Clinical | Neoplasms | Details | |
| Cenicriviroc mesylate/Tropifexor | LJC-242 | Phase 2 Clinical | Novartis Pharma Ag | Non-alcoholic Fatty Liver Disease | Details |
| Thioraviroc | Phase 1 Clinical | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | HIV Infections | Details | |
| Anti-CCR5 monoclonal antibody (Human Genome Sciences) | HGS-1025 | Glaxosmithkline Plc | Details | ||
| PF-04634817 | PF-4634817; PF-04634817; PF-46334817 | Pfizer Pharmaceuticals Ltd (China) | Details | ||
| INCB-009471 | INCB-9471; INCB-009471 | Incyte Corp | Details | ||
| AZD-5672 | AZD5672; AZD-5672 | Astrazeneca Plc | Details | ||
| AGT 103-T | AGT 103-T | American Gene Technologies International Inc | Details | ||
| Lamivudine/Maraviroc/Zidovudine | GSK-2838510 | Glaxosmithkline Plc | Details | ||
| BMS-813160 | BMS-813160 | Phase 2 Clinical | Bristol-Myers Squibb Company | Pancreatic Neoplasms; Hyperplasia; Diabetic Nephropathies; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Carcinoma, Hepatocellular | Details |
| SB-728-HSC | SB-728-HSC; SB-728-HSPC; SB-728mR-HSPC | Phase 1 Clinical | Sangamo Biosciences | HIV Infections | Details |
| Vicriviroc | SCH-D; MK-4176; SCH-417; Sch-417690 | Phase 2 Clinical | Merck & Co Inc | HIV Infections; Acquired Immunodeficiency Syndrome; Colorectal Neoplasms | Details |
| SB-728-T | SB-728mR-T; SB-728-T | Phase 2 Clinical | Sangamo Biosciences | HIV Infections | Details |
| Cenicriviroc mesylate | CCR5/CCR2 antagonist; TBR-652; CVC; TAK-652 | Phase 3 Clinical | Tobira Therapeutics Inc, Takeda Pharmaceutical Co Ltd | Prediabetic State; HIV Infections; Acquired Immunodeficiency Syndrome; Diabetes Mellitus, Type 2; Non-alcoholic Fatty Liver Disease; Liver Cirrhosis; Coronavirus Disease 2019 (COVID-19); AIDS Dementia Complex; Cholangitis, Sclerosing; Hepatic Insufficiency; Obesity; Cognition Disorders | Details |
| Leronlimab | PRO-140; PA-14; HuPRO-140 | Phase 3 Clinical | Cytodyn Inc | HIV Infections; Solid tumours; Non-alcoholic Fatty Liver Disease; Coronavirus Disease 2019 (COVID-19); Triple Negative Breast Neoplasms; Graft vs Host Disease | Details |
This web search service is supported by Google Inc.




